Life in the fast lane: clinical and immunohistological characteristics of tachycardia-induced cardiomyopathy—a retrospective study in 684 patients; [Leben auf der Überholspur: klinische und immunhistologische Eigenschaften der tachykardieinduzierten Kardiomyopathie – eine retrospektive Studie mit 684 Patienten]

被引：5
作者：
Spahic A. [1 ]
Chen T.-H. [2 ]
Geller J.C. [3 ]
Saenger J. [4 ]
Ohlow M.‑A. [5 ]
机构：
[1] Department of Cardiology, Zentralklinik, Robert-Koch-Allee 9, Bad Berka
[2] Center for emergency medicine, University Hospital Jena, Am Klinikum 1, Jena
[3] Department of invasive and interventional Electrophysiology, Zentralklinik, Robert-Koch-Allee 9, Bad Berka
[4] Institute of Pathology, Zentralklinik Bad Berka, Robert-Koch-Allee 9, Bad Berka
[5] Department of Cardiology, SRH Wald-Klinikum, Straße des Friedens 122, Gera
来源：
Herzschrittmachertherapie + Elektrophysiologie | 2020年 / 31卷 / 3期
关键词：
Atrial fibrillation; Cardiomyopathy; Endomyocardial biopsy; Heart failure; Histology;
D O I：
10.1007/s00399-020-00709-4
中图分类号：
学科分类号：
摘要：
Background: Tachycardia-induced cardiomyopathy (TCM) has been known for decades as a reversible form of non-ischemic cardiomyopathy. However, its mechanism and characteristics remain poorly understood. Objectives: This retrospective study investigated endomyocardial biopsy (EMB) samples from consecutive patients with TCM and compared them with samples from patients with dilated cardiomyopathy (DCM) and inflammatory cardiomyopathy (InCM). Materials and methods: A total of 684 patients (18 TCM, 170 DCM, 496 InCM) with recent-onset heart failure and reduced ejection fraction unrelated to valvular or ischemic heart disease were analyzed. Results: In the TCM group, 81% were male, the mean age was 60 ± 13 years, and 94% had heart failure symptoms ≥2 New York Heart Association (NYHA) class. At baseline (BL), 78% had atrial fibrillation/flutter and 12% other forms of tachycardia or frequent extrasystole. The ventricular rate was higher compared to DCM and InCM patients (122 ± 25 versus 78 ± 21; p < 0.001). Mean ejection fraction at BL was lower compared to DCM and InCM (27 ± 12% versus 39.0 ± 14.6%; p = 0.001), but improved to a significantly greater extent during follow-up (FU) (20% versus 6%; p < 0.001). At FU, heart rate and presence of sinus rhythm were similar in all groups; 69% of TCM patients underwent cardioversion or ablation. Compared with DCM patients, TCM patients had stronger myocardial expression of major histocompatibility complex (MHC) class II and an equal amount of infiltration with T‑cells/macrophages. Compared with InCM patients, the presence of T‑cells/macrophages was significantly lower in TCM. The marker of apoptosis (caspase 3) was comparably elevated in TCM/InCM patients. Conclusion: Tachycardia-induced cardiomyopathy is characterized by immunohistological changes comparable to DCM except for caspase 3 levels, which were similar to those in InCM. © 2020, Springer Medizin Verlag GmbH, ein Teil von Springer Nature.
引用
收藏
页码：292 / 300
页数：8
相关论文
共 29 条
  • [1] Caforio A.L., Pankuweit S., Arbustini E., Basso C., Gimeno-Blanes J., Felix S.B., Fu M., Helio T., Heymans S., Jahns R., Klingel K., Linhart A., Maisch B., McKenna W., Mogensen J., Pinto Y.M., Ristic A., Schultheiss H.P., Seggewiss H., Tavazzi L., Thiene G., Yilmaz A., Charron P., Elliott P.M., European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Current state of knowledge on etiology, diagnosis, management, and therapy of myocarditis: a position statement of the
  • [2] Cooper L.T., Baughman K.L., Feldman A.M., Frustaci A., Jessup M., Kuhl U., Levine G.N., Narula J., Starling R.C., Towbin J., Virmani R., The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology, Eur Heart J, 28, pp. 3076-3093, (2007)
  • [3] Deshmukh P.M., Krishnamani R., Romanyshyn M., Johnson A.K., Noti J.D., Association of angiotensin-converting enzyme gene polymorphism with tachycardia cardiomyopathy, Int J Mol Med, 13, 3, pp. 455-458, (2004)
  • [4] Dickstein K., Cohen-Solal A., Filippatos G., McMurray J.J., Ponikowski P., Poole-Wilson P.A., Stromberg A., van Veldhuisen D.J., Atar D., Hoes A.W., Keren A., Mebazaa A., Nieminen M., Priori S.G., Swedberg K., ESC Committee for Practice Guidelines (CPG). ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration wit
  • [5] Ellis E.R., Josephson M.E., Heart failure and tachycardia-induced cardiomyopathy, Curr Heart Fail Rep, 10, 4, pp. 296-306, (2013)
  • [6] Gopinathannair R., Etheridge S.P., Marchlinski F.E., Spinale F.G., Lakkireddy D., Olshansky B., Arrhythmia-induced cardiomyopathies: mechanisms, recognition, and management, J Am Coll Cardiol, 66, 15, pp. 1714-1728, (2015)
  • [7] Gossage A.M., Braxton Hicks J.A., On auricular fibrillation, Q J Med, 6, 4, pp. 435-440, (1913)
  • [8] Kajstura J., Zhang X., Liu Y., Szoke E., Cheng W., Olivetti G., Hintze H., Anversa P., The cellular basis of pacing-induced dilated cardiomyopathy: myocyte cell loss and myocyte cellular reactive hypertrophy, Circulation, 92, pp. 2306-2317, (1995)
  • [9] Kim D.Y., Kim S.H., Ryu K.H., Tachycardia induced cardiomyopathy, Korean Circ J, 49, 9, pp. 808-817, (2019)
  • [10] Leone O., Veinot J.P., Angelini A., Baandrup U.T., Basso C., Berry G., Bruneval P., Burke M., Butany J., Calabrese F., d'Amati G., Edwards W.D., Fallon J.T., Fishbein M.C., Gallagher P.J., Halushka M.K., McManus B., Pucci A., Rodriguez E.R., Saffitz J.E., Sheppard M.N., Steenbergen C., Stone J.R., Tan C., Thiene G., van der Wal A.C., Winters G.L., 2011 consensus statement on endomyocardial biopsy from the Association for European Cardiovascular Pathology and the Society for Cardiovascular Patho
123